Fidgetin-like 2 as a target to enhance wound healing

Abstract

Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.

What is claimed is: 
     
         1 . A method of inhibiting scarring in a subject comprising directly administering to a wound an amount of a siRNA or shRNA directed against a DNA or RNA encoding a human Fidgetin like-2 comprising the amino acid set forth in SEQ ID NO:2 effective to inhibit scarring. 
     
     
         2 . The method of  claim 1 , wherein the siRNA is administered. 
     
     
         3 . The method of  claim 1 , wherein the shRNA is administered. 
     
     
         4 . The method of  claim 1 , wherein the siRNA directed against a DNA or RNA encoding human Fidgetin-like 2 has at least one 2′ sugar modification. 
     
     
         5 . The method of  claim 4 , wherein the shRNA directed against a DNA or RNA encoding human Fidgetin-like 2 has at least one 2′ sugar modification. 
     
     
         6 . The method of  claim 1 , wherein the siRNA or shRNA is directed against an mRNA encoding the human Fidgetin-like 2. 
     
     
         7 . The method of  claim 2 , wherein the siRNA comprises a sequence set forth in SEQ ID NOS:3, 4, 5, 6, 7, 8, 9, or 10.